Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Therapy for Oligometastatic Esophageal Squamous Cell Carcinoma
NCT03904927Phase 2Completed
- Sponsor
- Fudan University
- Start
- Feb 2019
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free survival at 3 years. Started Feb 2019; status: completed.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03904927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904927.